Joshua Meisner, MD, PhD
Manage Your Profile
About
Dr. Meisner is a physician-scientist in Pediatric Cardiology at the University of Michigan. His clinical focus is in cardiovascular genetics collaborating in the hypertrophic cardiomyopathy, muscular dystrophy, cardiovascular genetics and aortopathy, and RASopathy multidisciplinary clinics. He also sees general cardiology and molecular and biochemical cardiology patients in his individual clinics. His translational research laboratory utilizes induced pluripotent stem cell cardiomyocyte (iPSC CM) and innovative mouse models to understanding the of pathophysiology and clinical course that leads to cardiomyopathy in children and young adults secondary to metabolic disorders (e.g. TANGO2 related metabolic encephalopathy and arrhythmia syndrome), growth signaling (e.g. RASopathies), and disruption of the cardiomyocyte contractile apparatus (e.g. MYBPC3 hypertrophic cardiomyopathy).
Qualifications
-
Pediatric Cardiology FellowshipUniversity of Michigan, Pediatric Cardiology, Ann Arbor, United States
2018 - 2021
Residency
-
Pediatric ResidentUniversity of Michigan, Pediatrics, Ann Arbor, United States
2015 - 2018
Residency
-
MD, PhD, Biomedical EngineeringUniversity of Virginia, Charlottesville, Virginia, United States
2006 - 2015
-
MS, Biomedical EngineeringTexas A&M University, College Station, Texas, United States
2005 - 2006
-
BS, Biomedical EngineeringTexas A&M University, College Station, Texas, United States
2000 - 2004
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
Research Overview
1. Mechanisms and translational therapeutics in MYBPC3 related hypertrophic cardiomyopathy
2. Outcomes in pediatric cardiomyopathy.
3. TANGO2 Related Metabolic Encephalopathy and Arrhythmia
4. Molecular guided therapies for pediatric cardiomyopathy
5. Role of lymphatic function in congenital heart disease and protein losing enteropathy
Recent Publications
-
Bita S, Spence C, Espahbodi N, Gwin C, Stephens S, Yetman A, Tierney S, Iannucci G, Sallee D, Nees S, Jones E, Camarda J, Holmes K, Drant S, Prakash S, Tunks R, McBridge K, Renella P, Dilorenzo M, Channing A, Steele J, Milewicz D, Meisner J, Lu J, Quezada Liuti E, Niaz T, Jacob B, Dawson T, Martin-Sheehan J, Soludczyk E, Weigand J, Morris S. 2026 Oct 4;Proceeding / Abstract / PosterLONGITUDINAL AORTIC ROOT GROWTH AND OUTCOMES IN PEDIATRIC MARFAN SYNDROME COMPARED BY BASELINE DILATION STATUS: A MULTICENTER STUDY FROM CLARITY
-
Renberg A, Coppersmith S, Merritt O, Heider A, Helms A, Michniacki T, Luxford J, Josephi-Taylor S, Roberts P, Meisner J. Am J Med Genet A, 2026 Apr 3;Journal ArticleTargeted Anti-IL-1 Immunomodulatory Therapy in Pediatric Onset PPP1R13L-Related Arrhythmogenic Cardiomyopathy.
DOI:10.1002/ajmg.a.70156 PMID: 41928611 -
Meisner J. 2026 May 8;PresentationDetermining the Mechanical and Metabolic Pathogenesis of MYBPC3 Related Hypertrophic Cardiomyopathy
-
Reeves S, Sloan-Heggen C, Whitt Z, Meisner J, Ames E, Lejman M. 2026 Mar 10;Proceeding / Abstract / PosterA Triple Diagnosis Case Illustrating the Need for Continued Re-Evaluation
-
Meisner J, Bullard A, Lange J, Friedline S, Previs M, Helms A. 2026 Mar 9;Proceeding / Abstract / PosterAAV Gene Replacement Therapy in Mybpc3 Related Hypertrophic Cardiomyopathy Mouse Model Improves Ventricular Function
-
Reeves S, Sloan-Heggen C, Lejman M, Whitt Z, Meisner J, Ames E. Genetics in Medicine Open, 2026 Mar 7; 4: 103901Journal ArticleP407: A triple diagnosis case illustrating the need for continued re-evaluation
DOI:10.1016/j.gimo.2026.103901 -
Russell MW, Meisner JK. Journal of the American College of Cardiology, 2026 Jan 1;Journal ArticlePreparing for Tomorrow, Today
DOI:10.1016/j.jacc.2026.04.007 -
2025 Oct 24;Presentation2025 TANGO2 Virtual Research Symposium